|Bid||1.1600 x 3000|
|Ask||1.1900 x 2900|
|Day's Range||1.1500 - 1.1900|
|52 Week Range||0.6200 - 3.5900|
|Beta (5Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.67|
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a Trial in Progress abstract for CI-8993, a first-in-class monoclonal anti-VISTA antibody, has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which will be held virtually from November 9-14, 2020.
This week we saw the Curis, Inc. (NASDAQ:CRIS) share price climb by 13%. But spare a thought for the long term...
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will provide a company overview at two upcoming investor conferences: